Compare PBT & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBT | JANX |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | PBT | JANX |
|---|---|---|
| Price | $31.51 | $17.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 18 |
| Target Price | N/A | ★ $33.81 |
| AVG Volume (30 Days) | 78.3K | ★ 751.0K |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | $194.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $57.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.25 | $12.12 |
| 52 Week High | $37.00 | $35.34 |
| Indicator | PBT | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 36.82 | 51.36 |
| Support Level | $30.72 | $15.90 |
| Resistance Level | $32.25 | $19.16 |
| Average True Range (ATR) | 1.15 | 0.83 |
| MACD | -0.22 | 0.07 |
| Stochastic Oscillator | 6.26 | 48.72 |
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.